<DOC>
	<DOCNO>NCT00510510</DOCNO>
	<brief_summary>This study assess safety/tolerability 28 day treatment NVA237 100 µg 200 µg day , compare placebo patient moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Safety Tolerability 28 Days Treatment With Glycopyrronium Bromide ( NVA237 ) ( 100 200 µg Once Day ) Patients With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age 40 year old Patients moderate severe COPD accord GOLD Guidelines ( 2006 ) Patients smoke history least 10 pack year Patients postbronchodilator Forced Expiratory Volume One Second ( FEV1 ) equal great 30 % predict normal value le 80 % predict normal value , postbronchodilator FEV1/FVC le 0.7 visit 2 Written informed consent patient prior initiation studyrelated procedure Patients require oxygen therapy daily basis chronic hypoxemia , hospitalize exacerbation airways disease 6 week prior visit 1 screening period ( visit 3 ) . Patients respiratory tract infection within 6 week prior visit 1 screening period ( visit 3 ) . Patients history asthma indicate ( limited ) : Blood eosinophil count &gt; 400/mm3 , onset symptom prior age 40 year . Patients history long QT syndrome whose QTc measure visit 1 prolong ( 440 m male 460 m female ) . Patients history untoward reaction sympathomimetic amine inhale medication component thereof . Patients , judgment investigator clinically relevant laboratory abnormality clinically significant condition ( limited ) unstable ischemic heart disease , leave ventricular failure , long term prednisone therapy , history myocardial infarction , arrhythmia , narrowangle glaucoma , symptomatic prostatic hyperplasia , bladderneck obstruction moderate severe renal impairment might compromise patient safety compliance , interfere evaluation , preclude completion study . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>glycopyrronium bromide</keyword>
	<keyword>antimuscarinic</keyword>
</DOC>